The discovery of cyclin-dependent kinases 4/6 (CDK4/6) inhibitors significantly reshaped the therapeutic landscape of hormone-receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (aBC)1. The gene discussed is ERBB2; the disease is breast carcinoma.